Pyrazolopyrimidine JAK inhibitor compounds and methods

US8999998B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Paul Gibbons · San Francisco, US
• Emily Hanan · Redwood City, US
• Wendy Liu · Foster City, US
• Joseph P. Lyssikatos · South San Francisco, US
• Steven R. Magnuson · South San Francisco, US
• Rohan Mendonca · South San Francisco, US
• Richard Pastor · South San Francisco, US
• Thomas E. Rawson · Mountain View, US
• Michael Siu · Burlingame, US
• Mark Edward Zak · San Mateo, US
• Aihe Zhou · San Jose, US
• Bing-Yan Zhu · South San Francisco, US

Key dates

• Filing date: Jul 2, 2010
• Grant date: Apr 7, 2015
• Expiry date: May 29, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.